These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 4319133)

  • 41. [Treatment of tuberculosis resistant to 1st line drugs with rifampycin and ethambutol, twice a week, with an initial supplement of kanamycin].
    Santiviago C; Estrada A; Zúñiga E; Sepúlveda R; Alvarez R; Gay O; Zimmermann I; Hiriart M; Orrego H; Farga V
    Rev Med Chil; 1971 Dec; 99(12):928-33. PubMed ID: 5157620
    [No Abstract]   [Full Text] [Related]  

  • 42. A triple regimen of streptomycin, isoniazid and ethambutol in untreated cases of pulmonary tuberculosis. 2.
    Oka S; Kayaba K
    Sci Rep Res Inst Tohoku Univ Med; 1970 Dec; 17(3):106-9. PubMed ID: 5525311
    [No Abstract]   [Full Text] [Related]  

  • 43. [Controlled trial of isoniazid.rifampicin.ethambutol regimen and isoniazid.rifampicin.pyrazinamide regimen in the primary chemotherapy for pulmonary tuberculosis (author's transl)].
    Kekkaku; 1980 Jan; 55(1):7-13. PubMed ID: 6988627
    [No Abstract]   [Full Text] [Related]  

  • 44. Split-drug regimens for the treatment of patients with sputum smear-positive pulmonary tuberculosis--a unique approach.
    Santha T; Rehman F; Mitchison DA; Sarma GR; Reetha AM; Prabhaker R;
    Trop Med Int Health; 2004 May; 9(5):551-8. PubMed ID: 15117298
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ethambutol and viomycin.
    Pyle MM
    Med Clin North Am; 1970 Sep; 54(5):1317-27. PubMed ID: 4319383
    [No Abstract]   [Full Text] [Related]  

  • 46. [Various biological tests on several groups of subjects with tuberculosis subjected respectively to monotherapy with isoniazid, viomycin, pyrazinamide, cycloserine, ethioniamide and kanamycin].
    DE SIMONI G; CATTANEO C
    Ann Ist Carlo Forlanini; 1962; 22():326-65. PubMed ID: 14026068
    [No Abstract]   [Full Text] [Related]  

  • 47. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
    Nolan CM; Goldberg SV
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Six-month short course chemotherapy containing pyrazinamide for initial treatment of pulmonary tuberculosis].
    Wada M; Yosiyama T; Yosikawa M; Ogata H; Sugie T; Nakasono T; Sugita H
    Kekkaku; 1994 Nov; 69(11):671-80. PubMed ID: 7837720
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Therapy of tuberculosis in the adult].
    Schrappe M; Wassermann K; Kroegel C
    Med Klin (Munich); 1995 Apr; 90(4):229-30. PubMed ID: 7776936
    [No Abstract]   [Full Text] [Related]  

  • 50. [Effect of the addition of the 3rd agent on the combined therapy with ethionamide and kanamycin in tuberculosis in the mice].
    Matsumiya T; Freerksen E; Rosenfeld M
    Jpn J Tuberc Chest Dis; 1970 Jul; 16(1):30-4. PubMed ID: 4991617
    [No Abstract]   [Full Text] [Related]  

  • 51. [Internal medicine treatment of pulmonary tuberculosis].
    Schaich W
    Med Klin; 1970 Sep; 65(36):1553-8. PubMed ID: 4995072
    [No Abstract]   [Full Text] [Related]  

  • 52. The clearance of theophylline is increased during the initial period of tuberculosis treatment.
    Ahn HC; Lee YC
    Int J Tuberc Lung Dis; 2003 Jun; 7(6):587-91. PubMed ID: 12797703
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of kanamycin in a triple regimen of kanamycin, cycloserine and ethionamide in the treatment of far-advanced cases of pulmonary tuberculosis with tubercle bacilli resistant to primary drugs.
    Oka S; Motomiya M; Kato S; Sato H; Fujimoto M
    Sci Rep Res Inst Tohoku Univ Med; 1967 Apr; 14(1):91-3. PubMed ID: 4968094
    [No Abstract]   [Full Text] [Related]  

  • 54. [Clinical evaluation of rifampicin for pulmonary tuberculosis. 3. A controlled trial on the clinical effects of chemotherapy with rifampicin-ethambutol and viomycin-ethambutol in retreatment cases of pulmonary tuberculosis].
    Donomae I; Fujita S; Gomi J; Hibino S; Horai Z
    Kekkaku; 1971 Sep; 46(9):371-7. PubMed ID: 4330662
    [No Abstract]   [Full Text] [Related]  

  • 55. Results of a 12-month regimen for drug-resistant pulmonary tuberculosis.
    Pérez-Guzmán C; Vargas MH; Martínez-Rossier LA; Torres-Cruz A; Villarreal-Velarde H
    Int J Tuberc Lung Dis; 2002 Dec; 6(12):1102-9. PubMed ID: 12546119
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Antitubercular chemotherapy].
    Jouveshomme S; Dautzenberg B
    Rev Mal Respir; 1997 Dec; 14 Suppl 5():S88-104. PubMed ID: 9496594
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Therapeutic effect of rifampicin on re-treatment cases of pulmonary tuberculosis. The second study: a study on the combined therapy of rifampicin with ethambutol and pyrazinamide, especially on intermittent therapy].
    Kekkaku; 1972 Dec; 47(12):457-66. PubMed ID: 4652424
    [No Abstract]   [Full Text] [Related]  

  • 58. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis.
    Mitchison DA
    Int J Tuberc Lung Dis; 1998 Jan; 2(1):10-5. PubMed ID: 9562106
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [On the effectiveness of rifampicin and ethambutol used in 3 different therapeutical schemes in drug-resistant chronic pulmonary tuberculosis].
    Andrian A; Ciobanu V; Cojocaru G; Borşaru I; Ciobanu D; Spirescu G; Roşianu D; Pescariu M
    Ftiziologia; 1971; 20(6):623-8. PubMed ID: 5162289
    [No Abstract]   [Full Text] [Related]  

  • 60. [Th 13-14 and PZA and CS in the treatment of chronic cavitary tuberculosis with bacterial resistance to classic antibacterial drugs].
    Zunić D
    Tuberkuloza; 1966; 18(5):429-40. PubMed ID: 16296047
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.